Steris Plc (STE) Expected to Announce Quarterly Sales of $630.00 Million
Analysts expect Steris Plc (NYSE:STE) to post sales of $630.00 million for the current fiscal quarter, Zacks Investment Research reports. Three analysts have issued estimates for Steris Plc’s earnings, with the highest sales estimate coming in at $634.40 million and the lowest estimate coming in at $624.00 million. Steris Plc posted sales of $646.42 million during the same quarter last year, which suggests a negative year over year growth rate of 2.5%. The company is expected to announce its next earnings results before the market opens on Wednesday, November 1st.
On average, analysts expect that Steris Plc will report full-year sales of $630.00 million for the current year, with estimates ranging from $2.57 billion to $2.63 billion. For the next fiscal year, analysts expect that the firm will post sales of $2.72 billion per share, with estimates ranging from $2.70 billion to $2.76 billion. Zacks’ sales calculations are an average based on a survey of sell-side research firms that follow Steris Plc.
Steris Plc (NYSE:STE) last announced its quarterly earnings results on Tuesday, August 8th. The medical equipment provider reported $0.85 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.80 by $0.05. Steris Plc had a return on equity of 11.39% and a net margin of 4.63%. The company had revenue of $608.00 million during the quarter, compared to the consensus estimate of $597.66 million. During the same period in the prior year, the company earned $0.79 earnings per share. The company’s revenue for the quarter was down 4.8% compared to the same quarter last year.
Several research analysts have recently weighed in on STE shares. Raymond James Financial, Inc. lifted their price objective on Steris Plc from $95.00 to $100.00 and gave the stock an “outperform” rating in a research report on Monday, October 16th. Zacks Investment Research raised Steris Plc from a “hold” rating to a “buy” rating and set a $92.00 price objective for the company in a research report on Tuesday, July 11th. BidaskClub lowered Steris Plc from a “strong-buy” rating to a “buy” rating in a research report on Monday, July 31st. Finally, KeyCorp reissued a “buy” rating and issued a $91.00 price objective on shares of Steris Plc in a research report on Tuesday, October 17th. Two investment analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. Steris Plc has a consensus rating of “Buy” and a consensus price target of $90.75.
Shares of Steris Plc (NYSE:STE) opened at 91.24 on Monday. The company has a market capitalization of $7.78 billion, a P/E ratio of 65.26 and a beta of 1.29. The firm has a 50 day moving average price of $88.45 and a 200 day moving average price of $81.51. Steris Plc has a one year low of $63.80 and a one year high of $91.49.
The firm also recently disclosed a quarterly dividend, which was paid on Thursday, September 28th. Stockholders of record on Tuesday, August 29th were given a $0.31 dividend. The ex-dividend date was Friday, August 25th. This is a positive change from Steris Plc’s previous quarterly dividend of $0.28. This represents a $1.24 annualized dividend and a dividend yield of 1.36%. Steris Plc’s dividend payout ratio (DPR) is 88.57%.
In related news, VP Karen L. Burton sold 3,270 shares of the business’s stock in a transaction dated Tuesday, August 15th. The stock was sold at an average price of $85.70, for a total value of $280,239.00. Following the completion of the sale, the vice president now directly owns 11,807 shares of the company’s stock, valued at approximately $1,011,859.90. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Mohsen Sohi sold 2,744 shares of the business’s stock in a transaction dated Wednesday, August 9th. The shares were sold at an average price of $85.98, for a total value of $235,929.12. Following the completion of the sale, the director now directly owns 21,816 shares of the company’s stock, valued at $1,875,739.68. The disclosure for this sale can be found here. Over the last three months, insiders sold 194,086 shares of company stock valued at $16,953,621. Corporate insiders own 2.55% of the company’s stock.
A number of institutional investors have recently modified their holdings of STE. Citigroup Inc. bought a new stake in Steris Plc in the 2nd quarter valued at about $206,000. Van Cleef Asset Management Inc bought a new stake in Steris Plc in the 2nd quarter valued at about $208,000. Cigna Investments Inc. New bought a new stake in Steris Plc in the 2nd quarter valued at about $209,000. BT Investment Management Ltd bought a new stake in Steris Plc in the 2nd quarter valued at about $210,000. Finally, Allegis Investment Advisors LLC bought a new stake in Steris Plc in the 2nd quarter valued at about $251,000. 93.33% of the stock is owned by institutional investors and hedge funds.
About Steris Plc
STERIS plc provides infection prevention and other procedural products and services. The Company operates through four segments: Healthcare Products, which offers infection prevention and procedural solutions for healthcare providers, including capital equipment and related maintenance, and installation services, as well as consumables; Healthcare Specialty Services, which provides a range of specialty services for healthcare providers, including hospital sterilization services, instrument and scope repairs, and linen management; Life Sciences, which offers capital equipment and consumable products, and equipment maintenance and specialty services for pharmaceutical manufacturers and research facilities, and Applied Sterilization Technologies, which offers contract sterilization and laboratory services for medical device and pharmaceutical customers and others.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Steris Plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Steris Plc and related companies with MarketBeat.com's FREE daily email newsletter.